EUCTR2005-001974-28-HU进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects.
GlaxoSmithKline R&D Limited0 个研究点目标入组 195 人开始时间: 2005年8月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Those who are 18 years or older at the time of the Screening Visit.
- •2. Those who have a minimum life expectancy greater than or equal to 3 months at the time of the Screening Visit.
- •3. Those who have cancer or are in remission from a recent cancer, and are taking opioid therapy for continued intractable pain. The opioid therapy must meet the following conditions:
- •comprised of one or more full opioid agonists
- •dosed chronically for at least one month prior to the Screening Visit at a minimum daily dose of at least 30 mg oral morphine equivalents
- •maintenance opioid therapy dosed for at least one month prior to screening visit
- •administered orally, transdermally, intravenously, or subcutaneously
- •4. Those who meet the protocol-definition of opioid-induced bowel dysfunction.
- •5. Those who understand the procedures, agree to participate in the study, and have signed and dated the informed consent form prior to the initiation of any study-related activities, including discontinuation of pre-study laxative regimen or other prohibited medications.
- •6. Those who are capable of completing the Daily Diary and paper questionnaires.
- •7. If female, the subject is currently either of:
- •a) non-childbearing potential
- •b) child-bearing potential, has a negative serum B-hCG pregnancy test at the Screening Visit (prior to investigational product) and agrees to use acceptable contraception throughout the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or lactating, or planning to become pregnant during the study.
- •2. Have participated in another trial with an investigational drug, device or procedure within 30 days prior to the Screening Visit. Subject has been randomized to investigational product in this study (SB-767905/008) or has been treated with alvimopan in another alvimopan trial at anytime in the past.
- •3. Unable to eat or drink. Subjects who are unable to take oral medications or to hold down oral medications due to vomiting are excluded.
- •4. Taking opioids for the management of drug addiction.
- •5. Taking opioids that are mixed agonists/antagonists or partial agonists.
- •6. Unable or unwilling to discontinue the use of and/or refrain from using stool softeners and laxatives of all types and formulation at the Screening Visit and throughout the Baseline and Treatment Periods. Subject is unable or unwilling to refrain from facilitating defecation via manual maneuvers (digital manipulation) throughout the study.
- •7. Has severe constipation that has not been appropriately managed such that the subject is at immediate risk of developing serious complications.
- •8. Have GI or pelvic disorders known to affect bowel transit, produce GI obstruction, or contribute to bowel dysfunction.
- •9. Has symptomatic primary or secondary brain tumour.
- •10. Currently taking vinca alkyloids or plans to take vinca alkyloids during the study.
- •11. In the investigators opinion has bowel dysfunction that is predominantly resulting from causes other than the chronic use of opioids.
- •12. Concomitant medications with known attribution to constipation are allowed if in the investigator’s opinion, the opioid therapy and not the concomitant medication is the predominant cause of the constipation.
- •13. Have chronic fecal incontinence.
- •14. Taking antidiarrheals (e.g., loperamide), has an incidence of diarrhea or loose stools in the 2 weeks prior to the Screening Visit or a history of intermittent diarrhea, loose stools or irritable bowel syndrome (IBS) symptoms which are consistent with the Rome II Criteria.
- •15. In the investigators opinion, has an uncontrolled systemic disease that would contraindicate participation in this study.
- •16. Has undergone prior radiation therapy that resulted in documented chronic radiation enteritis or radiation stricture, has undergone abdominal radiation therapy in the 2 weeks prior to the Screening Visit, is currently undergoing abdominal radiation therapy and/or plans to undergo abdominal radiation therapy during the study.
- •17. Have clinically significant laboratory abnormalities prior to Randomization that are suggestive of primary hepatic dysfunction or active viral hepatitis, renal impairment or any other condition that would contraindicate participation in this study.
- •18. Has a history of alcohol and/or substance abuse within the past 2 years.
- •19. Has any other known condition or physical examination finding prior to Randomization, which could contraindicate participation in this study.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectioCrohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2019-000886-19-ATMillennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)96
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer PaiEUCTR2005-001725-28-ATGlaxoSmithKline R & D Limited750
进行中（未招募）
1 期
An efficacy and safety study of ARGX-113 in patients with myasthenia gravis who have generalized muscle weakness.Myasthenia GravisEUCTR2018-002132-25-NLargenx BVBA150
进行中（未招募）
1 期
A Phase 2b study to demonstrate the safety and efficacy of Tildrakizumab in patients with Active Psoriatic ArthritisMedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000018188Psoriatic ArthritisEUCTR2016-003937-62-HUSUN Pharma Global FZE360
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes MellitusMedDRA version: 14.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2012-002414-39-ITMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.4,202